Daniel Curcio¹, Laura I. Barcelona², Wanda Cornistein³, Carlos Bantar⁴, Laura Barcan⁵, Pablo Bonvehí⁶, Rosa Reina⁷, Carlos Bergallo⁸, Héctor Biondi⁹, Jorge Calderón¹⁰, Jorge Castagnino⁹, Paulo Chinchilla¹¹, María Cecilia Dignani¹², Amadeo Esposto⁷, Norma Falcón Pérez¹³, Cristina Freuler¹⁴, Carlos M. Luna¹⁵,  Fernando Ríos¹⁶, Claudia Rodriguez³, Ricardo Valentini⁶, Walter Vazquez¹⁷, Sergio Verbanaz¹⁸ and Gabriel Vergara¹⁹

¹Instituto Sacre Cour, Infectología Institucional SRL., Buenos Aires, Argentina. ²Hospital Bernado Houssay, Buenos Aires, Argentina. ³Hospital Dr. Cosme Argerich, Buenos Aires, Argentina. ⁴Hospital San Martín, Paraná, Argentina. ⁵Hospital Italiano, Buenos Aires, Argentina. ⁶Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina. ⁷Hospital Interzonal de Agudos General San Martín, La Plata, Argentina. ⁸Sanatorio Allende, Córdoba, Argentina. ⁹Sanatorio de la providencia, Buenos Aires, Argentina. ¹⁰Policlínico Neuquén, Neuquén, Argentina. ¹¹Clínica de la Ciudad, Buenos Aires, Argentina. ¹²Fundacion de Lucha contra la Leucemia (FUNDALEU), Buenos Aires, Argentina. ¹³Complejo Médico Policía Federal Argentina Churruca Visca, Buenos Aires, Argentina. ¹⁴Hospital Alemán, Buenos Aires, Argentina. ¹⁵Hospital de Clínicas José de San Martín, Buenos Aires, Argentina. ¹⁶Hospital Nacional Prof. A. Posadas, Buenos Aires, Argentina. ¹⁷Hospital Español, Mendoza, Argentina. ¹⁸Hospital Británico, Buenos Aires, Argentina. ¹⁹Hospital Ramos Mejía, Buenos Aires, Argentina.

Abstract

Tigecycline is the first of a new class of antibiotics named glycylcyclines and is active in vitro against a variety of gram-positive and gram-negative organisms, including nosocomial resistant pathogens such as vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase-producing Enterobacteriaceae, and multidrug-resistant-Acinetobacter spp. This medication has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia. Tigecycline’s pharmacological and microbiological profile has also encouraged physicians’ to use the drug in other infections caused by resistant pathogens featuring limited therapeutics options (i.e. hospital-acquired pneumonia-HAP). In this study we publish the conclusions of an expert panel that identify and evaluate the evidence to support the use of Tigecycline in hospitalized patients with one of the following three infections: cSSSI, cIAI and HAP, including ventilator-associated pneumonia. Based on this data the panel developed an Algorithm Rational to Prescribe Tigecycline (ART) for each pathology.